Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
复制标题
对接受转导骨髓细胞的初次和二次移植法布里小鼠的多个器官进行长期酶校正和脂质减少。
DOI:
10.1073/pnas.120177997
复制
发表时间:
2000
影响因子:
11.1
通讯作者:
Medin,JA
中科院分区:
文献类型:
--
作者:
Takenaka,T;Murray,GJ;Qin,G;Quirk,JM;Ohshima,T;Qasba,P;Clark,K;Kulkarni,AB;Brady,RO;Medin,JA
Fabry disease is a compelling target for gene therapy as a treatment strategy. A deficiency in the lysosomal hydrolase α-galactosidase A (α-gal A; EC 3.2.1.22) leads to impaired catabolism of α-galactosyl-terminal lipids such as globotriaosylceramide (Gb3). Patients develop vascular occlusions that cause cardiovascular, cerebrovascular, and renal disease. Unlike for some lysosomal storage disorders, there is limited primary nervous system involvement in Fabry disease. The enzyme defect can be corrected by gene transfer. Overexpression of α-gal A by transduced cells results in secretion of this enzyme. Secreted enzyme is available for uptake by nontransduced cells presumably by receptor-mediated endocytosis. Correction of bystander cells may occur locally or systemically after circulation of the enzyme in the blood. In this paper we report studies on long-term genetic correction in an α-gal A-deficient mouse model of Fabry disease. α-gal A-deficient bone marrow mononuclear cells (BMMCs) were transduced with a retrovirus encoding α-gal A and transplanted into sublethally and lethally irradiated α-gal A-deficient mice. α-gal A activity and Gb3 levels were analyzed in plasma, peripheral blood mononuclear cells, BMMCs, liver, spleen, heart, lung, kidney, and brain. Primary recipient animals were followed for up to 26 weeks. BMMCs were then transplanted into secondary recipients. Increased α-gal A activity and decreased Gb3 storage were observed in all recipient groups in all organs and tissues except the brain. These effects occurred even with a low percentage of transduced cells. The findings indicate that genetic correction of bone marrow cells derived from patients with Fabry disease may have utility for phenotypic correction of patients with this disorder.
登录
查看更多内容
影响因子:
4.2
作者:
T. Takenaka;G. Qin;R. Brady;J. Medin
通讯作者:
J. Medin
DOI:
10.1073/pnas.94.6.2540
发表时间:
1997-03-18
影响因子:
11.1
作者:
Ohshima, T;Murray, GJ;Kulkarni, AB
通讯作者:
Kulkarni, AB
DOI:
10.1073/pnas.93.15.7917
发表时间:
1996-07-23
影响因子:
11.1
作者:
Medin, JA;Tudor, M;Brady, RO
通讯作者:
Brady, RO
影响因子:
5.1
作者:
FJ Novo;D. Górecki;G. Goldspink;K. Macdermot
通讯作者:
K. Macdermot
DOI:
--
发表时间:
2006
期刊:
Identification of the Tmtsp genes encoding a novel cell-surface protein with the thrombospondin-1 domain 107
影响因子:
--
作者:
Takayanagi;S.;Hiroyama;T.;Yamazaki;S.;Nakajima;T.;Morita;Y.;Usui;J.;Eto;K.;Motohashi;T.;Shiomi;K.;Keino-Masu;K.;Masu;M.;Oike;Y.;Mori;S.;Yoshida;N.;Iwama;A.and Nakauchi;H
通讯作者:
H